Search Results
Your search for Colorectal matches 3239 pages
Showing 901 - 950
Heinz-Josef Lenz, MD, on Colorectal Cancer: Update From the CheckMate 9X8 Trial on Nivolumab, mFOLFOX6, and Bevacizumab
Heinz-Josef Lenz, MD, of USC Norris Comprehensive Cancer Center, discusses phase II results from the CheckMate 9X8 study, which compared nivolumab plus fluorouracil/leucovorin/oxaliplatin (mFOLFOX6) and bevacizumab vs mFOLFOX6 and bevacizumab in the first-line treatment of metastatic colorectal...
Addition of Diet and Lifestyle Factors to Recurrence and Mortality Prediction Models for Patients With Stage III Colon Cancer
In a study reported in the Journal of Clinical Oncology, Cheng et al found that the addition of patient-reported diet and lifestyle factors to prediction models based on clinical and pathologic characteristics improved predictions of disease recurrence and mortality among patients with stage III...
Personalized Lung Cancer Risk Assessment Using a Blood-Based Biomarker Panel
In a study reported in the Journal of Clinical Oncology, Fahrmann et al found that a four-component blood-based biomarker panel showed predictive ability for the development of lung cancer. Prediction was improved when the panel was used in conjunction with the Prostate, Lung, Colorectal and...
UICC to Launch 3-Year Campaign to Create More Equitable Access to Cancer Services
On February 4, 2022, the Union for International Cancer Control (UICC) will launch a new 3-year campaign for World Cancer Day that brings together individuals, organizations, and governments around the world in an effort to create awareness and help close the gap in cancer care. The campaign...
Mehmet Altan, MD, on Solid Tumors: Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab
Mehmet Altan, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase Ib dose-escalation study, which showed early evidence of activity for NKTR-255, an investigational IL-15 receptor agonist, plus cetuximab in patients with solid tumors. Treatment appeared to lead ...
Palliative Care Use Among Commercially Insured U.S. Patients With Metastatic Cancer: 2001–2016
In a study reported in JCO Oncology Practice, Ferrario et al found that while use of palliative care among commercially insured patients aged 25 to 64 years in the United States with metastatic cancer has increased since 2001, use remained at 40% among patients with very poor–prognosis cancers in...
Study Uses Data From a Nationally Representative Colonoscopy Registry to Gather Information on Early-Onset Colorectal Precancerous Lesions
In a study published in the journal Gastroenterology, Trivedi et al described an increase in early-onset colorectal cancer and precancerous polyps, based on a large, nationally representative study of patients younger than 50 who underwent colonoscopy. It was the first large-scale study to look at...
Single-Cell Transcriptomic and Imaging Atlas of Colorectal Polyps Provides Insights for Cancer Surveillance
A team of researchers has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the disease. Their study, published by Chen et al in the journal Cell, describes findings using a single-cell transcriptomic and imaging...
Does Geography Play a Role in Early-Onset Colorectal Cancer in Young Black Men?
Although the incidence and mortality rates in colorectal cancer have dropped by 3.6% each year from 2007 to 2016 for people aged 55 and older—mainly because of increased colorectal cancer screening, advances in therapy, and reductions in smoking—these rates have increased by 2% each year during the ...
Comparison of Efficiency of USPSTF vs PLCO Criteria in Determining Eligibility for Lung Cancer Screening
In an interim analysis of a prospective cohort study reported in The Lancet Oncology, Tammemägi et al found that the Prostate Lung Colorectal and Ovarian Cancer Screening Trial 2012 risk prediction model (PLCOm2012) may be more efficient than U.S. Preventive Services Task Force 2013 (USPSTF2013)...
Recruiting Practices to Help Test Performance Measures to Advance Oncology Quality of Care
ASCO is currently recruiting practices to participate in measures testing for a variety of efforts, including re-endorsing existing measures by the National Quality Forum (NQF). In addition to ensuring the highest level of quality care for individuals with cancer and advancing the specialty of...
I Don’t Know Why I Got Young-Onset Colorectal Cancer
Throughout my adolescence and early adulthood, I had been plagued with digestive issues, including bouts of gastritis and constipation, which seemed normal for me and wasn’t too concerning. But by the time I turned 30, in 2015, the acid reflux I had been experiencing became so frequent and...
2021 FDA Approvals of Drugs for Cancer Treatment
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to many novel drugs and new indications for older therapeutic agents used in oncology and hematology. NOVEMBER Pafolacianine for Ovarian Cancer Lesions: On November 29, pafolacianine (Cytalux), an imaging drug,...
Study Examines Rates of Breast and Colorectal Cancer Screening Among Rural Women
Women who live in urban areas and those residing in rural areas are screened for breast cancer at similar rates, but rural women are screened for colorectal cancer at significantly lower rates than their urban counterparts, research published by Shete et al in JAMA Network Open showed. The...
Solving the Conundrum of Young-Onset Colorectal Cancer
Although research so far has failed to uncover the root causes of the development of young-onset colorectal cancer, what is certain is that although colorectal cancer rates are declining in older adults, they are on a steady rise in people younger than age 50, especially those between the ages of...
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...
Colorectal Cancer Screening: Preferences of Gastroenterologists and Primary Care Clinicians
Despite the availability of several effective screening tests, colorectal cancer screening rates remain below national goals. Although colonoscopy is the most often recommended screening method, a new study has found that the preferences of primary care clinicians have shifted toward noninvasive...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutant Colorectal Cancer
In a prespecified analysis of the phase II CodeBreaK100 trial reported in The Lancet Oncology, Marwan Fakih, MD, and colleagues found that the KRAS G12C protein inhibitor sotorasib showed modest activity in patients with previously treated KRAS G12C–mutant colorectal cancer. Study Details The...
The National Cancer Act of 1971
On December 23, 1971, President Richard M. Nixon signed the National Cancer Act into law. At that time, cancer was the nation’s second leading cause of death; only about one of two people diagnosed with cancer survived at least 5 years—compared with two of three people diagnosed with the disease...
Expect Questions on Use of Low-Dose Aspirin to Help Prevent Colorectal Cancer
Following a review of new data and additional analyses of previous data concerning colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) “concluded the evidence is inadequate that low-dose aspirin use reduces colorectal cancer incidence or mortality.”1 Consequently, a draft...
Update on the Role of Low-Dose Aspirin in Colorectal Cancer Prevention
Updating its 2016 recommendation on the use of aspirin to prevent cardiovascular disease and colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement. It noted the potential harms of daily aspirin, with the most serious being bleeding in the...
Profiles of Cancer Risk Associated With Immune-Mediated Diseases
In a study reported in JAMA Oncology, He et al found that individuals with immune-mediated diseases were at an increased risk of developing cancer, with organ-specific immune-mediated diseases being more strongly associated with local vs extralocal cancers. Study Details The prospective cohort...
Help Test Performance Measures to Advance Oncology Quality of Care
ASCO is currently recruiting practices to participate in measures testing for a variety of efforts, including re-endorsing existing measures by the National Quality Forum (NQF). In addition to ensuring the highest level of quality care for individuals with cancer and advancing the specialty of...
Update on the Incidence of NSCLC: Focus on Need to Implement Widescale Screening
Recent articles in JAMA Oncology focused on lung cancer and screening strategies. Apar Kishor Ganti, MD, MS, of the University of Nebraska Medical Center, Omaha, and colleagues provided updated data on non–small cell lung cancer (NSCLC) incidence, prevalence, and stage through 2017.1 Sylvia K....
Association of TP53 Gain-of-Function and Non–Gain-of-Function Mutations With Outcomes in Left-Sided vs Right-Sided Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Pan et al found that overall survival was poorer among patients with metastatic right-sided vs left-sided colorectal cancer with TP53 mutations, driven by poorer outcomes in those with non–gain-of-function mutations, and that gain-of-function ...
Telemedicine Use Among U.S. Patients With Newly Diagnosed Cancer: Impact of Socioeconomic Status
In a study reported in a research letter in JAMA Oncology, Katz et al found that higher socioeconomic status was associated with greater use of telemedicine among patients with newly diagnosed cancers in the United States between January and August 2020. As stated by the investigators, “The...
Researchers Identify Significant Differences in Tumor Characteristics Between Younger and Older Patients With Cancer
Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older patients with cancer across several cancer types. Their research, published by Shah et al in Cell Reports, suggests that cancer treatment could...
Trends in Incidence of Colorectal Cancer Among Black and White Individuals Aged 40 to 49 Years From 2000 to 2017
In a study reported in JAMA Network Open, Montminy et al found that the incidence of colorectal adenocarcinoma in people aged 40 to 49 years in the United States has increased in White individuals and remained stable in Black individuals between 2000 and 2017, with incidence rates being equivalent...
Five Percent Overall Medicare Reimbursement Cut Estimated for Medical Oncology in 2022
On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the 2022 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) final rule. Although ASCO will analyze the rule in greater detail in the coming days, initial highlights from the rule are outlined...
No Disease-Free Survival Difference With Longer Anastrozole Treatment After Endocrine Therapy in HR-Positive Breast Cancer
In an Austrian Breast and Colorectal Cancer Study Group phase III trial (ABCSG-16/SALSA) reported in The New England Journal of Medicine, Michael Gnant, MD, of the Comprehensive Cancer Center, Medical University of Vienna, and colleagues found no difference in disease-free survival with 2 vs 5...
Expert Point of View: Paul Wheatley-Price, MRCP
During an International Association for the Study of Lung Cancer (IASLC) press briefing, Paul Wheatley-Price, MRCP, commented as the patient advocate on the panel. Dr. Wheatley-Price is Associate Professor of Medicine at the University of Ottawa, lung cancer disease site lead at Ottawa Hospital...
In Case You Missed It: Brief Highlights From ESMO Congress 2021
The ASCO Post has published a wealth of practice-changing studies and news about other advances presented during the European Society for Medical Oncology (ESMO) Congress 2021. In addition to the biggest news from this international meeting, here are several summaries of interesting study findings...
Long-Term Outcomes With Chemoradiotherapy Before vs After Chemotherapy in the Total Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Long-term results of a German phase II trial (CAO/ARO/AIO-12) reported in JAMA Oncology by Fokas et al showed similar disease outcomes, chronic toxicity, and quality of life with chemoradiotherapy before vs after chemotherapy in the total neoadjuvant treatment of patients with locally advanced...
Thomas Gruenberger, MD, Shares Thoughts on Radiotherapy for Colorectal Liver Metastases
Invited discussant of the phase III EPOCH trial, Thomas Gruenberger, MD, a surgical oncologist at the Clinic Favoriten, Health Network Vienna, noted that the trial’s “intention was fulfilled,” thus making it the “first positive phase III trial that prolonged both progression-free and hepatic...
For Liver Metastases, Transarterial Radioembolization With Yttrium-90 Plus Chemotherapy May Delay Disease Progression
In the international phase III EPOCH trial, patients with colorectal liver metastases who experienced disease progression on first-line therapy derived significant benefit from treatment with transarterial yttrium Y-90 radioembolization in combination with systemic chemotherapy, according to Mary...
Treatment Adherence, Toxicity, and Outcomes With Adjuvant Fluoropyrimidine Plus Oxaliplatin in Early-Onset Colorectal Cancer
In an analysis of data from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) database reported in the Journal of Clinical Oncology, Fontana et al found a greater risk of relapse and cancer-specific mortality after adjuvant fluoropyrimidine/oxaliplatin chemotherapy in patients...
U.S. Multisociety Task Force on Colorectal Cancer Releases Updated Screening Recommendations
The U.S. Multisociety Task Force on Colorectal Cancer—representing the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy—has updated its colorectal cancer screening recommendations, which were last published...
Medication Nonadherence Among Cancer Survivors: Are Indirect Health-Care Costs to Blame?
Approximately 1 in 10 long-term survivors of cancer fails to take medications as prescribed due to financial hardship, according to research presented at the 2021 ASCO Quality Care Symposium.1 However, indirect health-care costs—not drug copays—may be responsible, the study investigators ...
Study Finds Lack of Health Insurance May Hinder Recommended Cancer Screening in Unemployed Adults
In a recent study published by Stacey Fedewa, PhD, and colleagues in the journal Cancer, unemployed individuals were less likely to have health insurance and be up to date on getting recommended cancer screening tests. Analyses revealed that their lack of health insurance coverage accounted for...
Expert Point of View: Michaela A. Dinan, PhD
The invited discussant of the study on out-of-pocket costs of cancer care, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, Connecticut, underscored the study’s key...
Out-of-Pocket Costs on the Rise for the Four Most Common Cancers, Study Finds
Rising cost-sharing requirements from private insurance have exacerbated the financial burden for patients with cancer, according to research presented at the 2021 ASCO Quality Care Symposium.1 Analysis of claims data on the four most prevalent cancers in the United States—female breast,...
Do Solid Organ Transplant Recipients With a Previous Cancer Diagnosis Have High Cure Probabilities?
In a study reported in the Journal of Clinical Oncology, Engels et al found that patients with a previous cancer diagnosis who underwent solid organ transplantation had high cancer cure probabilities. Additionally, posttransplantation cancer-specific survival was associated with cancer cure...
Study Evaluates Virtual vs In-Person Visits and Access to Lung Cancer Screening
Findings from a novel telemedicine effort to screen patients for lung cancer screening during the COVID-19 pandemic show that virtual single-visit screenings may be just as effective as single-visit screenings done in person, according to a study presented by Magarinos et al at the American College ...
Do Diet-Related Molecules Play a Role in the Development of Aggressive Prostate Cancer?
Cleveland Clinic researchers have shown that diet-associated molecules in the gut may be associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. These findings were published by Reichard et al in Cancer Epidemiology, Biomarkers & Prevention. While...
First-Round Results of Prostate Cancer Screening for Men With Pathogenic Variants in Mismatch Repair Genes
As reported in The Lancet Oncology by Bancroft et al, the first round of prostate cancer screening in the IMPACT study of men with pathogenic variants in mismatch repair genes showed an increased risk of prostate cancer in carriers of MSH2 and MSH6 variants compared with noncarrier controls. As...
Study Finds Similar Survival Rates Among Patients With Metastatic Colorectal Cancer Younger and Older Than Age 50
Even though patients with metastatic colorectal cancer younger than age 50 tend to be more fit and receive more intensive treatment than older patients, survival for both groups is roughly the same, according to a study published by Lipsyc-Sharf et al in the Journal of the National Cancer...
Expert Point of View: Pierre Laurent-Puig, MD
The invited discussant of the FOCUS4-C trial was Pierre Laurent-Puig, MD, Professor of Medicine, Université de Paris, Institut du Cancer Paris CARPEM. According to Dr. Laurent-Puig, the “promising results” for the WEE1 inhibitor adavosertib in colorectal cancer in the FOCUS4-C trial could apply to ...
FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer
The novel WEE1 inhibitor adavosertib, given after induction chemotherapy, yielded a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with metastatic colorectal cancer and TP53/RAS mutations, according to the randomized phase II FOCUS4-C trial....
Annual Report to the Nation, Part 2: Focus on Patient Economic Burden Associated With Cancer Care
Part 2 of the latest Annual Report to the Nation on the Status of Cancer—provided by the American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries—has found that patients with cancer in the United...
Expert Point of View: Federica Di Nicolantonio, MD, PhD
“KRAS G12C inhibitors as monotherapy yield a relatively low overall response rate, but when you combine them with an EGFR [epidermal growth factor receptor] inhibitor, the response rate is nearly double,” said Federica Di Nicolantonio, MD, PhD, Professor of Oncology at the University of Turin in...
